Phase IIb trial of RAVAX in patients with active rheumatoid arthritis.
Latest Information Update: 12 Dec 2013
Price :
$35 *
At a glance
- Drugs IR 501 (Primary) ; IR 703 vaccine (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Immune Response Corporation
- 13 Jul 2012 Primary endpoint 'American-College-of-Rheumatology-20%-response-criteria' has not been met.
- 05 Nov 2010 New trial record.